No Data
Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
Ladenburg Thalmann Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $2
ENeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $5